Celator Pharmaceuticals, Inc. Announces New Data on Factors Associated With Outcomes in AML Patients Treated With CPX-351
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing new and more effective therapies to treat cancer, today announced that a new analysis of data from two randomized Phase 2 studies of CPX-351 (cytarabine:daunorubicin) Liposome Injection in patients with acute myeloid leukemia (AML) has confirmed the consistent activity of CPX-351 and identified several prognostic factors for outcomes in the studies. The results were presented at the American Society of Clinical Oncology 2013 Annual Meeting in Chicago, IL (ASCO Abstract #7100).
Help employers find you! Check out all the jobs and post your resume.
PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing new and more effective therapies to treat cancer, today announced that a new analysis of data from two randomized Phase 2 studies of CPX-351 (cytarabine:daunorubicin) Liposome Injection in patients with acute myeloid leukemia (AML) has confirmed the consistent activity of CPX-351 and identified several prognostic factors for outcomes in the studies. The results were presented at the American Society of Clinical Oncology 2013 Annual Meeting in Chicago, IL (ASCO Abstract #7100).
Help employers find you! Check out all the jobs and post your resume.